Valentina V. Ishkaraeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina V. Ishkaraeva has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Irina E. Zazerskaya
Almazov National Medical Research Centre
4 shared publications - Kseniia A. Rudenko
Almazov National Medical Research Centre
2 shared publications - Albina I. Dukovich
V.A. Almazov National Medical Research Center
1 shared publication - Alina O. Godzoyeva
V.A. Almazov National Medical Research Centre
1 shared publication - Alina Yur'EVna Babenko
Almazov National Medical Research Center
1 shared publication - Anna A. Kuznetsova
Almazov National Medical Research Centre
1 shared publication
Latest Publications
- 23 June 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (3) , 38-48
Clinical and morphological characteristics of patients with placental abruption
BACKGROUND: Placental abruption of a normally located placenta remains one of the most severe obstetric complications of pregnancy, associated with a high risk of maternal and perinatal morbidity and mortality. Current studies indicate the polyetiological nature of placental abruption, emphasizing the key role of uteroplacental vascular disorders associated with chronic arterial hypertension, preeclampsia, and other forms of endothelial dysfunction. Investigation of placental morphological changes in placental abruption is essential for understanding the causes and pathogenesis of this condition, identifying risk factors, optimizing pregnancy management, and preventing recurrence. AIM: The aim of this study was to evaluate the relationship between clinical manifestations and placental morphofunctional characteristics in placental abruption of a normally located placenta. METHODS: This retrospective case–control study included 14 patients delivered at the Almazov National Medical Research Centre, St. Petersburg, Russia in 2023–2024. Two study groups were formed: Group I (the main group) consisted of pregnant women with isolated placental abruption (n = 7); Group II (the control group) consisted of pregnant women with placental abruption complicated by preeclampsia (n = 7). Placental specimens were examined histologically in the Laboratory of Morphology at the Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia using standard hematoxylin and eosin staining. Statistical data analysis was performed using the Python 3 programming language, the VisualStudioCode code editor, and the Pandas and SciPy application libraries. RESULTS: The study groups were comparable in baseline clinical characteristics, with differences identified in the severity and structure of gestational complications. In the group with placental abruption complicated by preeclampsia (Group II), severe preeclampsia was diagnosed in 43% of cases; in one patient (14% of cases), it developed in the presence of chronic arterial hypertension, while moderate preeclampsia associated with chronic arterial hypertension was observed in two patients (29% of cases). Despite a more complicated clinical course in the combined pathology group, emergency delivery allowed for achievement of comparable perinatal outcomes. Histological examination revealed distinct differences in placental morphology between the study groups. Placental abruption complicated by preeclampsia was characterized by chronic placental insufficiency, impaired villous maturation (hypoplasia and immaturity), and pronounced circulatory disorders. In isolated placental abruption, acute hemodynamic disturbances and focal placental ischemia predominated. These differences account for variations in the clinical course and potential perinatal outcomes in placental abruption depending on the presence of preeclampsia. CONCLUSION: The findings of this study are consistent with global trends. Placental abruption complicated by preeclampsia is associated with chronic maternal vascular malperfusion and impaired placental perfusion, whereas isolated placental abruption is characterized by an acute pattern of placental injury.
- 23 June 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (3) , 38-48
Clinical and morphological characteristics of patients with placental abruption
BACKGROUND: Placental abruption of a normally located placenta remains one of the most severe obstetric complications of pregnancy, associated with a high risk of maternal and perinatal morbidity and mortality. Current studies indicate the polyetiological nature of placental abruption, emphasizing the key role of uteroplacental vascular disorders associated with chronic arterial hypertension, preeclampsia, and other forms of endothelial dysfunction. Investigation of placental morphological changes in placental abruption is essential for understanding the causes and pathogenesis of this condition, identifying risk factors, optimizing pregnancy management, and preventing recurrence. AIM: The aim of this study was to evaluate the relationship between clinical manifestations and placental morphofunctional characteristics in placental abruption of a normally located placenta. METHODS: This retrospective case–control study included 14 patients delivered at the Almazov National Medical Research Centre, St. Petersburg, Russia in 2023–2024. Two study groups were formed: Group I (the main group) consisted of pregnant women with isolated placental abruption (n = 7); Group II (the control group) consisted of pregnant women with placental abruption complicated by preeclampsia (n = 7). Placental specimens were examined histologically in the Laboratory of Morphology at the Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia using standard hematoxylin and eosin staining. Statistical data analysis was performed using the Python 3 programming language, the VisualStudioCode code editor, and the Pandas and SciPy application libraries. RESULTS: The study groups were comparable in baseline clinical characteristics, with differences identified in the severity and structure of gestational complications. In the group with placental abruption complicated by preeclampsia (Group II), severe preeclampsia was diagnosed in 43% of cases; in one patient (14% of cases), it developed in the presence of chronic arterial hypertension, while moderate preeclampsia associated with chronic arterial hypertension was observed in two patients (29% of cases). Despite a more complicated clinical course in the combined pathology group, emergency delivery allowed for achievement of comparable perinatal outcomes. Histological examination revealed distinct differences in placental morphology between the study groups. Placental abruption complicated by preeclampsia was characterized by chronic placental insufficiency, impaired villous maturation (hypoplasia and immaturity), and pronounced circulatory disorders. In isolated placental abruption, acute hemodynamic disturbances and focal placental ischemia predominated. These differences account for variations in the clinical course and potential perinatal outcomes in placental abruption depending on the presence of preeclampsia. CONCLUSION: The findings of this study are consistent with global trends. Placental abruption complicated by preeclampsia is associated with chronic maternal vascular malperfusion and impaired placental perfusion, whereas isolated placental abruption is characterized by an acute pattern of placental injury.
- 1 January 2025
- Published by ECO-Vector LLC (Publications)
Clinical Pharmacology Handbook for Obstetricians and Gynecologists. Edited by Irina E. Zazerskaya, Mikhail V. Pchelintsev, Andrei N. Kubynin
This clinical pharmacology handbook is organized according to the nosological principle of the ICD-10 classification and contains information on the necessary diagnostic and pharmacotherapeutic measures for conditions encountered in obstetric and gynecological practice. The book describes the drugs that are approved in the Russian Federation. The systematic organization of this large body of material allows the physician to easily determine a diagnostic and treatment plan based on current guidelines, select a drug by its international nonproprietary or brand name, verify its dosage, route of administration, and therapy duration, and provide a prescription. The handbook is intended for obstetricians and gynecologists to use in their daily practice. It will also be helpful to continuing education students at the departments of obstetrics and gynecology and clinical pharmacology.
- 1 January 2025
- Published by ECO-Vector LLC (Publications)
Clinical Pharmacology Handbook for Obstetricians and Gynecologists. Edited by Irina E. Zazerskaya, Mikhail V. Pchelintsev, Andrei N. Kubynin
This clinical pharmacology handbook is organized according to the nosological principle of the ICD-10 classification and contains information on the necessary diagnostic and pharmacotherapeutic measures for conditions encountered in obstetric and gynecological practice. The book describes the drugs that are approved in the Russian Federation. The systematic organization of this large body of material allows the physician to easily determine a diagnostic and treatment plan based on current guidelines, select a drug by its international nonproprietary or brand name, verify its dosage, route of administration, and therapy duration, and provide a prescription. The handbook is intended for obstetricians and gynecologists to use in their daily practice. It will also be helpful to continuing education students at the departments of obstetrics and gynecology and clinical pharmacology.
- 26 March 2024
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 73 (1) , 137-148
Pathogenetic traits of preeclampsia in COVID-19. A relevant literature review
The aim of this study was to present the latest data on the association of preeclampsia and coronavirus infection and on the preeclampsia-like syndrome, and to analyze the current literature on the pathogenetic relationships between COVID-19 and preeclampsia and on morphological changes in placental tissue in patients with these gestational complications. A significant portion of studies indicate an increased risk of developing preeclampsia in patients with coronavirus infection during pregnancy, regardless of gestational age, especially in severe COVID-19, but other researchers report no association between coronavirus infection and the onset of preeclampsia. The supposed pathogenetic connection between these pathologies consists in the development of systemic endothelial dysfunction and dysregulation of the renin-angiotensin-aldosterone system, while the direct effect of SARS-CoV-2 on the placentation is poorly understood and is a subject of debate. A new concept of the so-called “preeclampsia-like syndrome” has been introduced, which presumably occurs in patients with a severe form of the novel coronavirus infection as its extrapulmonary manifestation. The measurement of the ratio of soluble fms-like tyrosine kinase-1 activity to the level of placental growth factor ratio has been proposed as a differential diagnostic test between preeclampsia and the preeclampsia-like syndrome, but its prognostic value remains ambiguous. The morphological examination of placentas in patients with coronavirus infection and preeclampsia indicates the signs of maternal and fetal vascular malperfusion. The literature on the association between coronavirus infection and preeclampsia remains controversial, however, the better half of the researchers is indicative of a significant increase in the risk of developing this serious complication in pregnant women with COVID-19, especially for its severe form. New information about the preeclampsia-like syndrome, as well as the virtual absence of studies of placental morphology in patients with preeclampsia and coronavirus infection during pregnancy, dictate the need for further study to better understand the association between these two pathologies, determine the possibilities of patient surveillance and prevent complications.
- 26 March 2024
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 73 (1) , 137-148
Pathogenetic traits of preeclampsia in COVID-19. A relevant literature review
The aim of this study was to present the latest data on the association of preeclampsia and coronavirus infection and on the preeclampsia-like syndrome, and to analyze the current literature on the pathogenetic relationships between COVID-19 and preeclampsia and on morphological changes in placental tissue in patients with these gestational complications. A significant portion of studies indicate an increased risk of developing preeclampsia in patients with coronavirus infection during pregnancy, regardless of gestational age, especially in severe COVID-19, but other researchers report no association between coronavirus infection and the onset of preeclampsia. The supposed pathogenetic connection between these pathologies consists in the development of systemic endothelial dysfunction and dysregulation of the renin-angiotensin-aldosterone system, while the direct effect of SARS-CoV-2 on the placentation is poorly understood and is a subject of debate. A new concept of the so-called “preeclampsia-like syndrome” has been introduced, which presumably occurs in patients with a severe form of the novel coronavirus infection as its extrapulmonary manifestation. The measurement of the ratio of soluble fms-like tyrosine kinase-1 activity to the level of placental growth factor ratio has been proposed as a differential diagnostic test between preeclampsia and the preeclampsia-like syndrome, but its prognostic value remains ambiguous. The morphological examination of placentas in patients with coronavirus infection and preeclampsia indicates the signs of maternal and fetal vascular malperfusion. The literature on the association between coronavirus infection and preeclampsia remains controversial, however, the better half of the researchers is indicative of a significant increase in the risk of developing this serious complication in pregnant women with COVID-19, especially for its severe form. New information about the preeclampsia-like syndrome, as well as the virtual absence of studies of placental morphology in patients with preeclampsia and coronavirus infection during pregnancy, dictate the need for further study to better understand the association between these two pathologies, determine the possibilities of patient surveillance and prevent complications.
- 18 May 2023
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 72 (2) , 5-17
Prognostic value of anti- and proangiogenic factors in severe preeclampsia
BACKGROUND:Over the years, preeclampsia has remained a common pathology of pregnancy. Its severe form poses a significant threat to the health of the woman and the fetus. To assess the risk of developing preeclampsia, biochemical screening for placental growth factor and soluble tyrosine kinase-1 is carried out. The soluble glycoprotein endoglin, which regulates angiogenesis by influencing cell activation, adhesion, and migration, can supplement the idea of the imbalance of vascular factors in severe preeclampsia. A holistic study of anti- and proangiogenic factors can significantly complement the diagnosis of preeclampsia at the preclinical stage and a look at the course and treatment of this pregnancy complication. AIM:The aim of this work was to evaluate the concentrations of anti- and proangiogenic factors (soluble glycoprotein endoglin, soluble tyrosine kinase-1, placental growth factor) and compare the obtained data with the clinical manifestations of severe preeclampsia. MATERIALS AND METHODS:This case-control study included 81 pregnant women. The main group consisted of patients with severe preeclampsia (n= 41), while the control group comprised individuals with normal pregnancy (n= 40). To determine soluble glycoprotein endoglin levels in biological fluids, we used a new ELISA kit developed in the Laboratory of Hybridoma Technology, Academician A.M. Granov Russian Research Center for Radiology and Surgical Technologies (Saint Petersburg, Russia). placental growth factor and soluble tyrosine kinase-1 concentrations were assessed by electrochemiluminescence immunoassay using commercial Roche Diagnostics kits. Statistical analysis was performed using the StatTech v.3.0.6 program (Stattech Ltd., Russia). RESULTS:When analyzing the concentrations of anti- and proangiogenic factors (soluble glycoprotein endoglin in the blood serum and urine, soluble tyrosine kinase-1, placental growth factor and the ratio of these factors), depending on the study group, statistically significant results were obtained (p 0.05). The diagnostic significance of serum and urine soluble glycoprotein endoglin levels in predicting the probability of severe preeclampsia was assessed by the method of ROC curve analysis. Statistically significant differences (p 0.05) were found in the analysis of the concentrations of anti- and pro-angiogenic factors depending on the clinical manifestations such as systolic blood pressure 160 mm Hg (except for placental growth factor level), a multiple increase in urine soluble glycoprotein endoglin level with massive proteinuria, an increase in soluble glycoprotein endoglin levels in biological fluids with an increase in edematous syndrome. Correlation analysis revealed a significant relationship between anti- and proangiogenic factors and the term of delivery, as well as urine soluble glycoprotein endoglin level and the duration of the treatment. CONCLUSIONS:The data obtained complement the concept of severe preeclampsia. Knowing the concentrations of soluble glycoprotein endoglin in the blood serum and urine allows for predicting the timing of delivery and the possible duration of treatment, which is critical in the management of patients with severe preeclampsia.
- 18 May 2023
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 72 (2) , 5-17
Prognostic value of anti- and proangiogenic factors in severe preeclampsia
BACKGROUND:Over the years, preeclampsia has remained a common pathology of pregnancy. Its severe form poses a significant threat to the health of the woman and the fetus. To assess the risk of developing preeclampsia, biochemical screening for placental growth factor and soluble tyrosine kinase-1 is carried out. The soluble glycoprotein endoglin, which regulates angiogenesis by influencing cell activation, adhesion, and migration, can supplement the idea of the imbalance of vascular factors in severe preeclampsia. A holistic study of anti- and proangiogenic factors can significantly complement the diagnosis of preeclampsia at the preclinical stage and a look at the course and treatment of this pregnancy complication. AIM:The aim of this work was to evaluate the concentrations of anti- and proangiogenic factors (soluble glycoprotein endoglin, soluble tyrosine kinase-1, placental growth factor) and compare the obtained data with the clinical manifestations of severe preeclampsia. MATERIALS AND METHODS:This case-control study included 81 pregnant women. The main group consisted of patients with severe preeclampsia (n= 41), while the control group comprised individuals with normal pregnancy (n= 40). To determine soluble glycoprotein endoglin levels in biological fluids, we used a new ELISA kit developed in the Laboratory of Hybridoma Technology, Academician A.M. Granov Russian Research Center for Radiology and Surgical Technologies (Saint Petersburg, Russia). placental growth factor and soluble tyrosine kinase-1 concentrations were assessed by electrochemiluminescence immunoassay using commercial Roche Diagnostics kits. Statistical analysis was performed using the StatTech v.3.0.6 program (Stattech Ltd., Russia). RESULTS:When analyzing the concentrations of anti- and proangiogenic factors (soluble glycoprotein endoglin in the blood serum and urine, soluble tyrosine kinase-1, placental growth factor and the ratio of these factors), depending on the study group, statistically significant results were obtained (p 0.05). The diagnostic significance of serum and urine soluble glycoprotein endoglin levels in predicting the probability of severe preeclampsia was assessed by the method of ROC curve analysis. Statistically significant differences (p 0.05) were found in the analysis of the concentrations of anti- and pro-angiogenic factors depending on the clinical manifestations such as systolic blood pressure 160 mm Hg (except for placental growth factor level), a multiple increase in urine soluble glycoprotein endoglin level with massive proteinuria, an increase in soluble glycoprotein endoglin levels in biological fluids with an increase in edematous syndrome. Correlation analysis revealed a significant relationship between anti- and proangiogenic factors and the term of delivery, as well as urine soluble glycoprotein endoglin level and the duration of the treatment. CONCLUSIONS:The data obtained complement the concept of severe preeclampsia. Knowing the concentrations of soluble glycoprotein endoglin in the blood serum and urine allows for predicting the timing of delivery and the possible duration of treatment, which is critical in the management of patients with severe preeclampsia.